Antibody highly specific for diffuse systemic sclerosis (scleroderma).
Diffuse Cutaneous Systemic Sclerosis
Diffuse cutaneous systemic sclerosis is a form of scleroderma in which skin thickening spreads beyond the elbows and knees to the upper arms, thighs or trunk. It often progresses fastest in the first few years. It can also affect internal organs, especially the lungs, kidneys, heart and gut. Most people first notice Raynaud's phenomenon, puffy fingers or tight skin.
Lab tests linked to diffuse systemic sclerosis:
- Anti-Scl-70 (anti-topoisomerase I) antibodies: found in a share of people with the diffuse form. They are linked to a higher risk of lung scarring (interstitial lung disease).
- Doctors may also order ANA, anti-RNA polymerase III and anti-centromere antibodies, kidney function, urine tests, and blood pressure checks. Lung function tests, a lung CT scan and an echocardiogram are used to look for organ involvement.
How results are read:
- ANA is positive in almost everyone with systemic sclerosis. The specific antibody helps predict which organs are most at risk.
- Anti-Scl-70 points toward the diffuse form and lung involvement. Anti-RNA polymerase III is linked to a higher risk of kidney crisis.
- A positive antibody without symptoms does not diagnose systemic sclerosis. The diagnosis rests on skin and organ findings.
When to see a doctor:
- Get urgent care for a sudden rise in blood pressure, a severe headache, changes in vision or less urine. These can signal a scleroderma renal crisis.
- See your doctor about new or worsening breathlessness or a persistent dry cough.
Clinical takeaway: diffuse systemic sclerosis is diagnosed clinically, and antibodies such as anti-Scl-70 mainly help predict which organs need closest monitoring.
Biomarkers related to this condition
1 marker linked to this condition
Looking for a different marker? Browse all biomarkers →